Journal of Clinical Oncology, Vol 18, Issue 7
(April), 2000: 1481-1491
© 2000 American Society for Clinical Oncology
Health-Related Quality of Life in Patients Treated With Temozolomide Versus Procarbazine for Recurrent Glioblastoma Multiforme
By D. Osoba,
M. Brada,
W. K. A. Yung,
M. Prados
From Quality of Life Consulting, Vancouver, British Columbia, Canada; Institute of Cancer Research and Royal Marsden National Health Services Trust, Sutton, Surrey, United Kingdom; Department of Neuro-Oncology, M.D. Anderson Cancer Center, Houston, TX; and University of California, San Francisco, CA.
Address reprint requests to David Osoba, MD, QOL Consulting, 4939 Edendale Ct, West Vancouver, British Columbia, Canada V7W 3H7; email dosoba{at}bc.sympatico.ca
PURPOSE: To determine whether chemotherapy with temozolomide (TMZ) versus procarbazine (PCB) for recurrent glioblastoma multiforme (GBM) was associated with improvement in health-related quality of life (HRQOL).
PATIENTS AND METHODS: HRQOL was assessed at baseline and during treatment using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 and a Brain Cancer Module (BCM20) in two clinical trials that enrolled a total of 366 patients. Two hundred eighty-eight patients provided HRQOL data that could be used for analysis; 109 patients received TMZ in a phase II study, whereas 89 patients received TMZ and 90 received PCB in a randomized phase III study. Changes from baseline in the scores of seven preselected HRQOL domains (role and social functioning, global quality of life [QOL], visual disorders, motor dysfunction, communication deficit, and drowsiness) were calculated for all groups. Statistical significance, effect sizes, and proportions of patients with improved HRQOL scores (changes of  10 points) were calculated.
RESULTS: Before disease progression, patients treated with TMZ were found to have an improvement in most of the preselected HRQOL domain scores compared with their baseline (pretreatment) scores. Those who were progression-free on TMZ at 6 months had improvement in all the preselected HRQOL domains. Conversely, patients treated with PCB reported deterioration in HRQOL that was independent of whether or not the disease had progressed by 6 months. Patients with disease progression, regardless of treatment, experienced a sharp decline in all domains at the time of progression.
CONCLUSION: Treatment with TMZ was associated with improvement in HRQOL scores compared with treatment with PCB. The deterioration reported by PCB-treated patients was likely because of toxicity. Delaying disease progression by treatment with TMZ is beneficial to the HRQOL status of patients with recurrent GBM.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
G. Filippini, C. Falcone, A. Boiardi, G. Broggi, M. G. Bruzzone, D. Caldiroli, R. Farina, M. Farinotti, L. Fariselli, G. Finocchiaro, et al.
Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma
Neuro-oncol,
February 1, 2008;
10(1):
79 - 87.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J.B. Taphoorn, M. J. van den Bent, M. E.L. Mauer, C. Coens, J.-Y. Delattre, A. A. Brandes, P. A.E. Sillevis Smitt, H. J.J.A. Bernsen, M. Frenay, C. C. Tijssen, et al.
Health-Related Quality of Life in Patients Treated for Anaplastic Oligodendroglioma With Adjuvant Chemotherapy: Results of a European Organisation for Research and Treatment of Cancer Randomized Clinical Trial
J. Clin. Oncol.,
December 20, 2007;
25(36):
5723 - 5730.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Osoba
Translating the Science of Patient-Reported Outcomes Assessment Into Clinical Practice
J Natl Cancer Inst Monographs,
October 1, 2007;
2007(37):
5 - 11.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Keime-Guibert, O. Chinot, L. Taillandier, S. Cartalat-Carel, M. Frenay, G. Kantor, J.-S. Guillamo, E. Jadaud, P. Colin, P.-Y. Bondiau, et al.
Radiotherapy for Glioblastoma in the Elderly
N. Engl. J. Med.,
April 12, 2007;
356(15):
1527 - 1535.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. Grossman, K. A. Carson, T. T. Batchelor, G. Lesser, T. Mikkelsen, J. B. Alavi, S. Phuphanich, T. Hammour, J. D. Fisher, and J. G. Supko
The Effect of Enzyme-Inducing Antiseizure Drugs on the Pharmacokinetics and Tolerability of Procarbazine Hydrochloride
Clin. Cancer Res.,
September 1, 2006;
12(17):
5174 - 5181.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-B. Wasserfallen, S. Ostermann, S. Leyvraz, and R. Stupp
Cost of temozolomide therapy and global care for recurrent malignant gliomas followed until death
Neuro-oncol,
April 1, 2005;
7(2):
189 - 195.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. G. Fisher and P. A. Buffler
Malignant Gliomas in 2005: Where to GO From Here?
JAMA,
February 2, 2005;
293(5):
615 - 617.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. Brandes, A. Tosoni, U. Basso, M. Reni, F. Valduga, S. Monfardini, P. Amista, L. Nicolardi, G. Sotti, and M. Ermani
Second-Line Chemotherapy With Irinotecan Plus Carmustine in Glioblastoma Recurrent or Progressive After First-Line Temozolomide Chemotherapy: A Phase II Study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
J. Clin. Oncol.,
December 1, 2004;
22(23):
4779 - 4786.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Greanya, S. Taylor, F H. BscPharm, J Barnett, and B Thiessen
Temozolomide for malignant gliomas in British Columbia: A population-based cost-effectiveness analysis
Journal of Oncology Pharmacy Practice,
December 1, 2004;
10(4):
201 - 209.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. Tentori, C. Leonetti, M. Scarsella, G. d'Amati, M. Vergati, I. Portarena, W. Xu, V. Kalish, G. Zupi, J. Zhang, et al.
Systemic Administration of GPI 15427, a Novel Poly(ADP-Ribose) Polymerase-1 Inhibitor, Increases the Antitumor Activity of Temozolomide against Intracranial Melanoma, Glioma, Lymphoma
Clin. Cancer Res.,
November 1, 2003;
9(14):
5370 - 5379.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. H. Guyatt, D. Osoba, A. W. Wu, K. W. Wyrwich, G. R. Norman, and Clinical Significance Consensus Meeting Group
Methods to Explain the Clinical Significance of Health Status Measures
Mayo Clin. Proc.,
April 1, 2002;
77(4):
371 - 383.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. Tentori, C. Leonetti, M. Scarsella, G. d'Amati, I. Portarena, G. Zupi, E. Bonmassar, and G. Graziani
Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site
Blood,
March 15, 2002;
99(6):
2241 - 2244.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. B. Khan, J. J. Raizer, M. G. Malkin, K. A. Bazylewicz, and L. E. Abrey
A phase II study of extended low-dose temozolomide in recurrent malignant gliomas
Neuro-oncol,
January 1, 2002;
4(1):
39 - 43.
[Abstract]
[PDF]
|
|
|
|
|
|
|
Y. Hirose, M. S. Berger, and R. O. Pieper
Abrogation of the Chk1-mediated G2 Checkpoint Pathway Potentiates Temozolomide-induced Toxicity in a p53-independent Manner in Human Glioblastoma Cells
Cancer Res.,
August 1, 2001;
61(15):
5843 - 5849.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Hirose, M. S. Berger, and R. O. Pieper
p53 Effects Both the Duration of G2/M Arrest and the Fate of Temozolomide-treated Human Glioblastoma Cells
Cancer Res.,
March 1, 2001;
61(5):
1957 - 1963.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
B. A. Teicher, K. Menon, E. Alvarez, E. Galbreath, C. Shih, and M. Faul
Antiangiogenic and Antitumor Effects of a Protein Kinase C{beta} Inhibitor in Human T98G Glioblastoma Multiforme Xenografts
Clin. Cancer Res.,
March 1, 2001;
7(3):
634 - 640.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
D. Osoba, M. Brada, M. D. Prados, and W.K. A. Yung
Effect of disease burden on health-related quality of life in patients with malignant gliomas
Neuro-oncol,
October 1, 2000;
2(4):
221 - 228.
[Abstract]
[PDF]
|
|
|
|
